LOGIN  |  REGISTER
Cue Biopharma
Terns Pharmaceuticals

Stryker declares a $0.80 per share quarterly dividend

December 05, 2023 | Last Trade: US$364.60 7.46 2.09

Kalamazoo, Michigan, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.80 per share payable January 31, 2024 to shareholders of record at the close of business on December 29, 2023, representing an increase of 6.7% versus the prior year and previous quarter.

 “We continue to deliver strong growth and solid financial performance, and aligning with our capital allocation strategy we are raising our dividend 6.7%,” said Kevin Lobo, Chair and Chief Executive Officer.

Stryker is one of the world’s leading medical technology companies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in Medical and Surgical, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 130 million patients annually. More information is available at www.stryker.com.

Contacts

For investor inquiries please contact:
Jason Beach, Vice President, Investor Relations at 269-385-2600 or This email address is being protected from spambots. You need JavaScript enabled to view it. 

For media inquiries please contact:
Yin Becker, Vice President, Chief Corporate Affairs Officer at 269-385-2600 or This email address is being protected from spambots. You need JavaScript enabled to view it.

Chimerix

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB